Metz et al. [108] engineered a trivalent bi-specific Ab by linking a disulfide-stabilized variable fragment (dsFv), which is specific against c-Met antigen that is deregulated in several types of cancer [110], to the C-terminus of the heavy chain of a bivalent anti-HER3 Ab with one-armed protease substrate peptide (GPLGMLSQ, GPLGLWAQ and GPLGIAGQ for MMP-2 and MMP-9 [118], and GGGRR for urokinase plasminogen activator (uPA) [28]). This evidence concerns the gene PLAU and cancer.